MSF starts Ebola vaccination study targeting 20,000 DRC frontline workers
MSF and Epicentre launched BRAVO on 19 September to study the use of ERVEBO among 20,000 frontline workers in Ituri and North Kivu; the study will include vaccination and follow-up.
MSF and Epicentre launched BRAVO on 19 September to study the use of ERVEBO among 20,000 frontline workers in Ituri and North Kivu; the study will include vaccination and follow-up.
The study will assess ERVEBO use during the current Bundibugyo-virus outbreak. The vaccine is licensed against the Zaire species; MSF says any possible protection against Bundibugyo must be established through research. The planned study will last nine to 12 months, including three months of vaccination and at least six months of participant follow-up.
Hamad Medical Corporation says it has performed Qatar’s first subperiosteal jaw implant and reconstruction using three-dimensional imaging and virtual surgical planning. The procedure used custom components for a patient who was not suited to conventional implants.
A new clinic at Hamad General Hospital brings pulmonary and sleep medicine together with psychiatry to assess and treat non-respiratory sleep disorders in adults. Home sleep studies and overnight polysomnography may be used when needed.
Google Analytics can measure visits and site activity using cookies if you allow it. You can change your choice later.
Measurement and privacy details
Google Analytics measurement starts only if you allow it. After consent, automatic measurement may cover scrolls, outbound link clicks, downloads, video engagement, site searches and basic form interactions; search terms may be detected from URL parameters. This site’s own code does not send form field values; email redaction in automatic measurement is best-effort, not guaranteed. Our manual page-view event uses a cleaned URL. You can change your choice later. Visits that begin with consent may also send numeric LCP, INP and CLS performance measurements after Analytics loads. A first or later grant starts this on the next page load; withdrawing consent stops these performance reports for this page. The preference cookie lasts six months; advertising measurement and personalization stay off.
Your browser is sending a Global Privacy Control signal. Analytics is off by default; you may explicitly change this choice here.
